Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26127
Title: A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease.
Austin Authors: Khor, Yet H ;Saravanan, Kirushallini;Holland, Anne E ;Lee, Joanna Y T;Ryerson, Christopher J;McDonald, Christine F ;Goh, Nicole S L 
Affiliation: Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Department of Allergy, Immunology and Respiratory Medicine, Monash University, Melbourne, Australia
Department of Physiotherapy, Alfred Health, Melbourne, Australia
Centre for Heart Lung Innovation, Providence Health Care, Vancouver, BC, Canada
Respiratory and Sleep Medicine
Institute for Breathing and Sleep
Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia
Department of Respiratory Medicine, Alfred Health, Melbourne, Australia
Issue Date: 25-Mar-2021
metadata.dc.date: 2021-03-25
Publication information: Scientific reports 2021; 11(1): 6874
Abstract: Dyspnoea is a cardinal symptom of fibrotic interstitial lung disease (ILD), with a lack of proven effective therapies. With emerging evidence of the role of facial and nasal airflow for relieving breathlessness, this pilot study was conducted to examine the feasibility of conducting a clinical trial of a handheld fan (HHF) for dyspnoea management in patients with fibrotic ILD. In this mixed-methods, randomised, assessor-blinded, controlled trial, 30 participants with fibrotic ILD who were dyspnoeic with a modified Medical Research Council Dyspnoea grade ≥ 2 were randomised to a HHF for symptom control or no intervention for 2 weeks. Primary outcomes were trial feasibility, change in Dyspnoea-12 scores at Week 2, and participants' perspectives on using a HHF for dyspnoea management. Study recruitment was completed within nine months at a single site. Successful assessor blinding was achieved in the fan group [Bang's Blinding Index - 0.08 (95% CI - 0.45, 0.30)] but not the control group [0.47 (0.12, 0.81)]. There were no significant between-group differences for the change in Dyspnoea-12 or secondary efficacy outcomes. During qualitative interviews, participants reported that using the HHF relieved breathlessness and provided relaxation, despite initial scepticism about its therapeutic benefit. Oxygen-experienced participants described the HHF being easier to use, but not as effective for symptomatic relief, compared to oxygen therapy. Our results confirmed the feasibility of a clinical trial of a HHF in fibrotic ILD. There was a high level of patient acceptance of a HHF for managing dyspnoea, with patients reporting both symptomatic benefits and ease of use.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26127
DOI: 10.1038/s41598-021-86326-8
PubMed URL: 33767311
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on May 8, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.